School of Health Professions > Institute of Health Economics and Health Policy

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Date | Name | Item Type | Refereed | No Grouping
Jump to: 2024 | 2023 | 2022 | 2021 | 2020
Number of items at this level: 13.


Bilger, Jana Franziska; Pletscher, Mark; Müller, Tobias Benjamin (2024). Separating the wheat from the chaff: How to measure hospital quality in routine data? Health Services Research, 59(2), pp. 1-10. Wiley Online Library 10.1111/1475-6773.14282

Blankart, Katharina; Vandoros, Sotiris (2024). Explaining why increases in generic use outpace decreases in brand name medicine use in multisource markets and the role of regulation PLOS ONE, 19(5), e0301716. Public Library of Science 10.1371/journal.pone.0301716

Quiroga Gutierrez, Ana Cecilia; Boes, Stefan (2024). Bridging the gap: Experimental evidence on information provision and health insurance choices Health Economics, 33(6), pp. 1368-1386. Wiley 10.1002/hec.4820

Goetjes, Eva; Blankart, Katharina (2024). Insurance barriers and inequalities in health care access: evidence from dual practice Health Economics Review, 14(1) BioMed Central 10.1186/s13561-024-00500-y

Meier, Niklaus; Fuchs, Hendrik; Galactionova, Katya; Hermans, Cedric; Pletscher, Mark; Schwenkglenks, Matthias (2024). Cost-Effectiveness Analysis of Etranacogene Dezaparvovec Versus Extended Half-Life Prophylaxis for Moderate-to-Severe Haemophilia B in Germany PharmacoEconomics Open, 8(3), pp. 373-387. Springer 10.1007/s41669-024-00480-z


Gröble, Sabrina; Bilger, Jana Franziska; Britt, Chantal; Kaspar, Heidi; Schmitt, Kai-Uwe (2023). Der Transport zur Hämodialyse: Was kostet er und welche Auswirkung hat er auf das Leben der Betroffenen? Bern: Berner Fachhochschule, Departement Gesundheit, Akademie-Praxis-Partnerschaft

Barbier, Michaela Carla; Fengler, Alicia; Pardo, Esther; Bhadhuri, Arjun; Meier, Niklaus; Gautschi, Oliver (2023). Cost Effectiveness and Budget Impact of Nivolumab Plus Ipilimumab Versus Platinum Plus Pemetrexed (with and Without Bevacizumab) in Patients with Unresectable Malignant Pleural Mesothelioma in Switzerland PharmacoEconomics, 41(12), pp. 1641-1655. Springer 10.1007/s40273-023-01305-3

Trottmann, Maria; Blozik, Eva; Hilbig, Marcel; LoVerdi, Daniel; Pedruzzi, Marcello; Scherer, Tina; Weiss, Martina; Pletscher, Mark; Meier, Niklaus (2023). Real-world expenditures and survival time after CAR-T treatment for large B-cell lymphoma in Switzerland: a retrospective study using insurance claims data Swiss Medical Weekly, 153(9), s3441. EMH Schweizerischer Aerzteverlag 10.57187/s.3441

Ammann, Daniel; Bilger, Jana Franziska; Loiacono, Matthew M.; Oberle, Susanne G.; Dounas, Andreas; Manuel, Oriol; Pletscher, Mark (2023). Burden of seasonal influenza in the Swiss adult population during the 2016/2017–2018/2019 influenza seasons Influenza and other respiratory viruses, 17(11) Wiley 10.1111/irv.13218

Van Gestel, Raf; Broekman, Niels; Müller, Tobias Benjamin (2023). Surgeon supply and healthcare quality: Are revision rates for hip and knee replacements lower in hospitals that employ more surgeons? Health Economics, 32(10), pp. 2298-2321. Wiley 10.1002/hec.4727


Müller, Tobias; Schmid, Christian; Gerfin, Michael (2022). Rents for pills: Financial incentives and physician behavior Journal of health economics, 87, p. 102711. Elsevier 10.1016/j.jhealeco.2022.102711


Schoenenberger, Lukas Klaus; Schmid, Alexander; Tanase, Radu; Beck, Mathias; Schwaninger, Markus (2021). Structural Analysis of System Dynamics Models Simulation Modelling Practice and Theory, 110, p. 102333. Elsevier 10.1016/j.simpat.2021.102333


Müller, Tobias Benjamin; Boes, Stefan (2020). Disability insurance benefits and labor supply decisions: evidence from a discontinuity in benefit awards Empirical economics, 58(5), pp. 2513-2544. Springer 10.1007/s00181-018-1587-4

This list was generated on Tue Jun 25 03:54:31 2024 CEST.
Provide Feedback